Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Alexion Pharmaceuticals)"
Count: 226
Selected: 0
NCT IDTitle
NCT02329327A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)
NCT01994382Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
NCT05109390A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults
NCT05047484A Study of Multiple Doses of ALXN2050 in Healthy Adults
NCT05047458A Study of Single-dose ALXN2050 in Healthy Adults
NCT05016206A Study of the Cardiac Effects of Danicopan in Healthy Adults
NCT04940559Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants
NCT04935294Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction
NCT04889690Study of Multiple Doses of Danicopan in Healthy Participants
NCT04889677Study of a Single Dose of Danicopan in Healthy Participants
NCT04889391Study of Radiolabeled Danicopan in Healthy Male Participants
NCT03555539Study of Danicopan in Participants With Hepatic Impairment
NCT03472885Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab
NCT03384186A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants
NCT03181633A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT03124368A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
NCT03108274A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants
NCT03053102Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT00401947A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection
NCT00040144Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B
NCT00034359Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection
NCT04709094A Drug Interaction Study of Danicopan
NCT04709081A Drug Interaction Study of ACH-0145228
NCT05578846Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics
NCT05565092Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease
NCT05556096Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05501717Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants
NCT05428696Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants
NCT05396742Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers
NCT05389449A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
NCT05346354Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
NCT05319912A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults
NCT05319899A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults
NCT05314231Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
NCT05307978Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants
NCT05303324Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults
NCT05288829A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants
NCT05288816A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants
NCT05288673A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants
NCT05288660A Study of a Single Dose of ALXN1210 in Healthy Participants
NCT05274633Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT05259085Study of ALXN2050 in Participants With Hepatic Impairment
NCT05254613A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants
NCT05234567A Prospective Sub-Study of the Global Hypophosphatasia Registry
NCT05218096Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
NCT05202145Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants
NCT05097989Study of ALXN2050 in Proliferative Lupus Nephritis (LN) and Immunoglobulin A Nephropathy (IgAN)
NCT05047523Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
NCT05019521A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT04999020Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis